BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Receives Average Recommendation of "Buy" from Analysts

Key Points

• BeOne Medicines Ltd. has received an average recommendation of "Buy" from seven analysts, with an average 12-month price target of approximately $330.89.
• Recent insider activity includes Lai Wang selling 259 shares for around $79,000, and COO Xiaobin Wu selling nearly 40,000 shares valued at over $12.1 million.
• For the most recent quarter, BeOne Medicines reported $1.32 billion in revenue and an earnings per share of $0.84, exceeding analyst expectations.

Shares of BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) have received an average rating of "Buy" from the seven brokerages that are currently covering the company, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $330.8889.

ONC has been the topic of several research reports. Wall Street Zen raised shares of BeOne Medicines from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 9th. Morgan Stanley boosted their target price on shares of BeOne Medicines from $313.00 to $330.00 and gave the stock an "overweight" rating in a report on Friday, June 27th. Guggenheim boosted their target price on shares of BeOne Medicines from $350.00 to $365.00 and gave the stock a "buy" rating in a report on Thursday, August 7th. JPMorgan Chase & Co. boosted their target price on shares of BeOne Medicines from $321.00 to $345.00 and gave the stock an "overweight" rating in a report on Thursday, July 17th. Finally, Royal Bank Of Canada boosted their target price on shares of BeOne Medicines from $349.00 to $364.00 and gave the stock an "outperform" rating in a report on Thursday, August 7th.

Insider Activity

In other BeOne Medicines news, insider Lai Wang sold 259 shares of the business's stock in a transaction that occurred on Wednesday, July 30th. The shares were sold at an average price of $305.00, for a total transaction of $78,995.00. Following the sale, the insider directly owned 1,023,529 shares of the company's stock, valued at $312,176,345. The trade was a 0.03% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Xiaobin Wu sold 39,936 shares of the company's stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $305.06, for a total transaction of $12,182,876.16. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 203,730 shares of company stock worth $57,617,229. Company insiders own 6.62% of the company's stock.

Institutional Investors Weigh In On BeOne Medicines

A number of institutional investors have recently modified their holdings of ONC. Anchor Investment Management LLC bought a new stake in shares of BeOne Medicines in the 2nd quarter valued at $26,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of BeOne Medicines in the 2nd quarter valued at $28,000. Daiwa Securities Group Inc. bought a new stake in shares of BeOne Medicines in the 2nd quarter valued at $35,000. Farther Finance Advisors LLC bought a new stake in shares of BeOne Medicines in the 2nd quarter valued at $39,000. Finally, Signaturefd LLC bought a new stake in shares of BeOne Medicines in the 2nd quarter valued at $49,000. 48.55% of the stock is owned by institutional investors.

BeOne Medicines Trading Up 0.1%

Shares of BeOne Medicines stock opened at $308.91 on Wednesday. The firm has a market capitalization of $33.86 billion, a PE ratio of -178.56 and a beta of 0.27. The company has a current ratio of 1.95, a quick ratio of 1.72 and a debt-to-equity ratio of 0.04. The firm's 50 day moving average is $281.26 and its 200 day moving average is $258.11. BeOne Medicines has a 1 year low of $170.99 and a 1 year high of $330.63.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $0.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.36. The company had revenue of $1.32 billion for the quarter, compared to analyst estimates of $1.24 billion. BeOne Medicines had a negative net margin of 3.89% and a negative return on equity of 1.22%. Equities research analysts forecast that BeOne Medicines will post -5.82 earnings per share for the current fiscal year.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.